LOGIN  |  REGISTER
C4 Therapeutics
Cue Biopharma

InnovAge Announces Participation at the KeyBanc Capital Markets Healthcare Forum

March 04, 2025 | Last Trade: US$3.83 0.00 0.00

DENVER, March 04, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced that Patrick Blair, CEO, and Ben Adams, CFO will be speaking at the KeyBanc Capital Markets Healthcare Forum on Tuesday, March 18, 2025, at 3:45 p.m. PT. The virtual event will be webcast live, and a link for the event will be available online on the investor relations section of the Company’s website.

About InnovAge

InnovAge is a market leader in managing the care of high-cost, frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge’s patient-centered care model is designed to improve the quality of care our participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers and government payors — “win.” As of December 31, 2024, InnovAge served approximately 7,480 participants across 20 centers in six states. https://www.innovage.com.

Investor Contact:
Ryan Kubota
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Lara Hazenfield
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page